Skip to content

A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease

A Randomized Double-blind Clinical Study for the Effect of Qingzhi Huayu Prescription on SDLDL-C/LDL-C in Patients With Coronary Heart Disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002589
Enrollment
Unknown
Registered
2019-09-11
Start date
2019-09-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Atherosclerotic Heart Disease

Interventions

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Objectives: patients have coronary atherosclerotic heart disease (CAD) with high sdLDL-C. Selection criteria: 1) Age between 18 and 80 (including 18 and 80); 2) Gender is not limited; 3) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%. 4) sdLDL-C (>= 52.6mg/dL) 5) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.

Exclusion criteria

Exclusion criteria: 1) History of statin-related liver lesions and/or myopathy; 2) Patients with malignant tumors (excluding those cured); 3) Patients with serious diseases of heart, lung, kidney, brain and blood; 4) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.); 5) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period; 6) Participate in other clinical researchers at the same time; 7) Researchers think that it is not suitable for patients to participate in this study.

Design outcomes

Primary

MeasureTime frame
sdLDL-C;

Secondary

MeasureTime frame
TG;HDL-C;TC;LDL-C;

Countries

China

Contacts

Public ContactYang Tao

Shuguang Hospital affillated to Shanghai University of TCM

yangtao8579@163.com+86 13917577668

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026